



**Media Contact:**

Chris Shields, Director of Marketing, Natrix Separations  
603-552-2486  
[shields@natrixseparations.com](mailto:shields@natrixseparations.com)

FOR IMMEDIATE RELEASE:

**Natrix Separations Announces \$19 Million Series B Financing**

Burlington, ON, September 3, 2008 — Natrix Separations Inc., a privately held company that develops and manufactures novel purification products for use in the manufacture of Green Fuels, Biopharmaceuticals, Vaccines, Veterinary Pharmaceuticals, Nutraceuticals and Potable Water announced today that it has closed a Series B financing totaling \$19 Million. The round was led by D.E. Shaw Ventures of Cupertino, CA, and included existing investors the Canadian Medical Discoveries Fund, managed by JovInvestment Management Inc., part of Jovian Capital Corporation, and the venture capital arm of the Business Development Bank of Canada, BDC Venture Capital. The proceeds of this raise are being used to complete the construction of Natrix's ISO 9001 compliant commercial manufacturing facility, and to support the commercialization of Natrix's diverse portfolio of separation products based on the company's patented **adsept**<sup>™</sup> technology.

With this financing, Alexander Wong, a managing director of D. E. Shaw & Co., L.P. and head of D. E. Shaw Ventures, joins Natrix's Board of Directors. Dr. Wong brings to Natrix over 15 years of experience in venture capital and engineering management. Prior to joining D. E. Shaw Ventures, Dr. Wong was a partner at Apax Partners and a managing director at Intel Capital. "Alex brings a tremendous depth of knowledge and experience in growing successful technology-based companies to Natrix," said Lisa Crossley, CEO of Natrix Separations. "The fact that Natrix was able to attract a new investor of D. E. Shaw Ventures' calibre in the present economic environment validates the significant market potential of our platform technology and products."

"Natrix is a rare company that has created technology to enable a new generation of cost-effective, high performance products ranging from therapeutic drugs to nutraceuticals and ultrapure drinking water," said Wong. "Natrix has the potential to be game-changing for the multi-billion dollar separations industry, which plays a key role in producing these products."

Natrix Separation's proprietary **adsept**<sup>™</sup> technology allows end users to rapidly and selectively capture specific target molecules from a broad range of feed streams. Natrix's membrane-based chromatography products can be used to purify therapeutic drugs, produce high value

nutraceuticals from commodity food products, or remove harmful heavy metals from drinking water. “Natrix has a unique value proposition”, said Michael Cross, Senior Vice President, JovInvestment Management. ‘Its products address the unmet needs of customers in a variety of markets within the Separations space. This new investment will allow the company to diversify its product offerings and penetrate new markets in North America and abroad”.

“As the first institutional investor in Natrix, it is with great interest that we have followed the company’s tremendous progress since our initial investment”, said Victor Scutaru, Director, BDC Venture Capital. “This new round of financing comes at an exciting time in the company’s evolution and we look forward to continuing to contribute to Natrix’s success”.

### **About Natrix Separations, Inc.**

Natrix Separations is a privately held company that develops and manufactures high performance, single use and multi-cycle disposable chromatography products for the life science, bioprocessing, nutraceutical, food, beverage, potable water/wastewater markets. Natrix has developed a patented membrane-based chromatography technology that combines the high binding capacity, selectivity and specificity typical of resin-based chromatography with the high throughput and ease of use of traditional membrane products. Natrix is located at 5295 John Lucas Drive, Unit 6, Burlington, ON, L7L 6A8, Toll Free Phone: 1-866-990-6972, [www.natrixseparations.com](http://www.natrixseparations.com).

### **About BDC Venture Capital**

BDC Venture Capital is a major venture capital investor in Canada, active at every stage of a company’s development cycle, from seed through expansion. Its focus is on technology based businesses with high growth potential that are positioned to become dominant players in their markets. Established in 1975, BDC Venture Capital has invested in over 400 firms to date. It currently manages some \$500 million in venture capital investments in the life sciences, telecommunications, information technology, and advanced technology sectors, as well as investments in funds. Visit [www.bdc.ca](http://www.bdc.ca) for more information.

### **About D.E. Shaw Ventures**

D. E. Shaw Ventures is the venture capital unit of the D. E. Shaw group. The D. E. Shaw group is a global investment and technology development firm with more than 1,500 employees; approximately \$39 billion in aggregate investment capital as of July 1, 2008; and offices in North America, Europe, and Asia. Since its organization in 1988, the firm has earned an international reputation for financial innovation, technological leadership, and an extraordinarily distinguished staff.

### **About Jovian Capital Corporation**

Jovian (TSX: JOV) acquires, creates and grows financial services companies specializing in wealth and asset management. The Jovian group of companies (MGI Securities Inc., MGI Securities (USA) Inc., Rice Financial Group Inc., BetaPro Management Inc., Horizons Funds Inc., JovFunds Management Inc., JovFunds Inc., JovInvestment Management Inc., Leon Frazer & Associates Inc., T.E. Wealth and Felcom Data Services Inc.) manages \$15.0 billion of client

assets (\$5.8 billion in assets under management and \$9.2 billion in assets under administration). Additional information is available at [www.joviancapital.com](http://www.joviancapital.com) and [www.sedar.com](http://www.sedar.com).